Factsheet bio approved
1
Biomedical By fostering an ecosystem of excellence around biotechnology and medical technology, the Skolkovo Innovation Centre’s Biomedical Cluster has put in motion a process that aspires to build global market leaders in the life sciences industry. This cluster of internationally leading scientists using the latest facilities and techniques will enable us to produce cutting-edge research that leads to innovative technologies, instruments and services that will help improve the quality of healthcare worldwide. Russia, as elsewhere in the industrialised world, is facing the challenge of an ageing population that is putting increasing pressure on both public spending and the quality of healthcare – and this despite Russia having more physicians, hospitals and health care workers per capita than any other country in the world. But Russia’s biomedical industry accounts for only 0.2% of the world market and many Russian companies currently need to conduct their research abroad. To meet the challenges and reinforce Russia’s global performance in the sector, the Biomedical Cluster aspires to create a global research hub in Skolkovo to develop new and innovative solutions to current and future health challenges. At the same time it seeks to commercialise the innovations and to build a network/ecosystem of excellence tapping into expertise from around the world. To accomplish this mission, the cluster has iden- tified R&D priorities that not only reflect the global context, but also are informed by the standards of best practice in leading scientific centres around the world. Thus, our cluster will prioritise the following sectors of activity: • Clinical medicine & healthcare • Biomedical & life sciences • Bioinformatics, and • Industrial biotechnologies The cluster will not only design and carry out innovative research within these categories, but it will also oversee the entire commercialisation process to transform technology from the labo- ratory into marketable world class goods and services. The Biomedical Cluster brings leading international and Russian scientists together with entrepreneurs and venture capital funds. Cluster partners will have at their disposal an array of cutting-edge equipment, infrastructure and business services. 90 companies including Johnson & Johnson and its pharmaceutical branch Janssen Pharmaceutica and Immunotech Developments have already joined the cluster which each week receives additional applications for corporate participation. Our cluster is also rapidly developing strategic partnerships with leading universities and research institutes around the world. This truly global network includes: • Harvard Medical School • Tel Aviv University • Okinawa Institute of Science and Technology • King’s College London We also have strong support from a wide variety of public and private partners within the Russian Federation. The Ministry of Health and Social Development, the Ministry of Industry and Trade and the Ministry of Economic Development number among our partners as do major players from Russia’s biomedical industry including RVC, RUSNANO and EMBL. It is through the construction of this dynamic ecosystem of Russian and international companies, universities and public bodies that we can truly achieve our vision and form a global innovation hub. Prof Igor Goryanin is the Executive Director of the Biomedical cluster. In addition to his role in Skolkovo, Prof Goryanin holds the Henrik Kacser Chair in Computational Systems Biology at the University of Edinburgh and heads the Laboratory of Biological Systems, at the Okinawa Institute of Science and Technology (Japan). Prof Goryanin is well acquainted with working at the global level with international teams, having led several high profile international collaborations with research groups across Europe, China, Japan and the USA. Prof Goryanin also has the commercial and entrepreneurial background essential to ensure the cluster’s success, having co-founded and led Biobank Inc., Russia. For more information: http://www.sk.ru/en/ 02 02 Biomedical Cluster Factsheet Media kit Factsheet Russia has more physicians, hospitals and health care workers per capita than any other country in the world, but both its medical research and native pharmaceutical market are underdeveloped. The Biomedical Cluster is designed to help transform Russia’s pharmaceutical market into a $31.25 billion industry by 2015 by attracting the biggest names in medical research. Nuclear Biomedical Factsheet Space Energy IT Skolkovo 01 00 03 04 05 www.sk.ru/en factsheet_Bio_final:Layout 1 15/01/12 23:27 Page 1
-
Upload
the-skolkovo-foundation -
Category
Technology
-
view
299 -
download
1
Transcript of Factsheet bio approved
Biomedical
By fostering an ecosystem of excellence aroundbiotechnology and medical technology, theSkolkovo Innovation Centre’s Biomedical Clusterhas put in motion a process that aspires to buildglobal market leaders in the life sciences industry.This cluster of internationally leading scientistsusing the latest facilities and techniques willenable us to produce cutting-edge research thatleads to innovative technologies, instruments andservices that will help improve the quality ofhealthcare worldwide.
Russia, as elsewhere in the industrialised world, isfacing the challenge of an ageing population thatis putting increasing pressure on both publicspending and the quality of healthcare – and thisdespite Russia having more physicians, hospitalsand health care workers per capita than any othercountry in the world. But Russia’s biomedicalindustry accounts for only 0.2% of the worldmarket and many Russian companies currentlyneed to conduct their research abroad.
To meet the challenges and reinforce Russia’sglobal performance in the sector, the BiomedicalCluster aspires to create a global research hubin Skolkovo to develop new and innovativesolutions to current and future health challenges.At the same time it seeks to commercialise theinnovations and to build a network/ecosystem ofexcellence tapping into expertise from aroundthe world.
To accomplish this mission, the cluster has iden-tified R&D priorities that not only reflect theglobal context, but also are informed by the
standards of best practice in leading scientificcentres around the world.
Thus, our cluster will prioritise the following sectorsof activity:
• Clinical medicine & healthcare
• Biomedical & life sciences
• Bioinformatics, and
• Industrial biotechnologies
The cluster will not only design and carry outinnovative research within these categories, but itwill also oversee the entire commercialisationprocess to transform technology from the labo-ratory into marketable world class goods andservices.
The Biomedical Cluster brings leading internationaland Russian scientists together with entrepreneursand venture capital funds. Cluster partners willhave at their disposal an array of cutting-edgeequipment, infrastructure and business services.90 companies including Johnson & Johnsonand its pharmaceutical branch JanssenPharma ceutica and Immunotech Developmentshave already joined the cluster which each weekreceives additional applications for corporateparticipation.
Our cluster is also rapidly developing strategicpartnerships with leading universities and researchinstitutes around the world. This truly globalnetwork includes:
• Harvard Medical School
• Tel Aviv University
• Okinawa Institute of Science and Technology
• King’s College London
We also have strong support from a wide variety ofpublic and private partners within the RussianFederation. The Ministry of Health and SocialDevelopment, the Ministry of Industry and Tradeand the Ministry of Economic Developmentnumber among our partners as do major playersfrom Russia’s biomedical industry includingRVC, RUSNANO and EMBL. It is through the
construction of this dynamic ecosystem ofRussian and international companies, universitiesand public bodies that we can truly achieve ourvision and form a global innovation hub.
Prof Igor Goryanin is the Executive Director of theBiomedical cluster. In addition to his role inSkolkovo, Prof Goryanin holds the Henrik KacserChair in Computational Systems Biology at theUniversity of Edinburgh and heads the Laboratoryof Biological Systems, at the Okinawa Institute ofScience and Technology (Japan). Prof Goryanin iswell acquainted with working at the global levelwith international teams, having led several highprofile international collaborations with researchgroups across Europe, China, Japan and the USA.Prof Goryanin also has the commercial andentrepreneurial background essential to ensurethe cluster’s success, having co-founded and ledBiobank Inc., Russia.
For more information: http://www.sk.ru/en/
02
02Biomedical ClusterFactsheet
Mediakit
Factsheet
Russia has more physicians,hospitals and health care workers per capita than anyother country in the world, butboth its medical research andnative pharmaceutical marketare underdeveloped. TheBiomedical Cluster is designedto help transform Russia’spharmaceutical market into a$31.25 billion industry by 2015by attracting the biggest namesin medical research.
Nuclear
BiomedicalFactsheet
SpaceEnergyITSkolkovo0100 03 04 05
www.sk.ru/en
factsheet_Bio_final:Layout 1 15/01/12 23:27 Page 1
